Kenneth A Gruber
Overview
Explore the profile of Kenneth A Gruber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
39
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhu X, Potterfield R, Gruber K, Zhang E, Newton S, Norgard M, et al.
J Clin Invest
. 2024 Nov;
135(1).
PMID: 39509261
Cancer patients undergoing chemotherapy often experience anorexia and weight loss that substantially deteriorates overall health, reduces treatment tolerance and quality of life, and worsens oncologic outcomes. There are currently few...
2.
Axiak-Bechtel S, Leach S, Newton-Northup J, Milner R, Fox-Alvarez S, Fagman L, et al.
J Vet Intern Med
. 2023 Oct;
37(6):2344-2355.
PMID: 37897303
Background: The melanocortin 4 antagonist TCMCB07 is safe and effective in reversing cachexia caused by sepsis or cancer in rodents. The safety and pharmacokinetics of TCMCB07 are demonstrated in healthy...
3.
Gruber K, Ji R, Gallazzi F, Jiang S, Van Doren S, Tao Y, et al.
ACS Pharmacol Transl Sci
. 2022 May;
5(5):344-361.
PMID: 35592439
During the development of a melanocortin (MC) peptide drug to treat the condition of cachexia (a hypermetabolic state producing lean body mass wasting), we were confronted with the need for...
4.
Axiak-Bechtel S, Leach S, Scholten D, Newton-Northup J, Johnson B, Durham H, et al.
Pharmacol Res Perspect
. 2021 May;
9(3):e00777.
PMID: 34014033
The melanocortin-4 receptor (MC4R) antagonistic peptide TCMCB07 was developed for the treatment of cachexia. The objectives of this study were to examine pharmacokinetics and safety of TCMCB07 administered subcutaneously to...
5.
Hu Y, Gruber K, Smith D
J Cachexia Sarcopenia Muscle
. 2020 Jul;
11(6):1677-1687.
PMID: 32725770
Background: Cachexia is a debilitating, life-threatening condition whose pathology includes reduced food intake accompanied by hypermetabolism, leading to a catabolic state. The hypothalamic melanocortin system is a critical regulator of...
6.
Zhu X, Callahan M, Gruber K, Szumowski M, Marks D
J Clin Invest
. 2020 Jun;
130(9):4921-4934.
PMID: 32544087
Cachexia, a devastating wasting syndrome characterized by severe weight loss with specific losses of muscle and adipose tissue, is driven by reduced food intake, increased energy expenditure, excess catabolism, and...
7.
Gruber K, Fan W, Akerberg H, Larhammar D, Chee M, Colmers W, et al.
Endocrine
. 2009 Apr;
35(3):312-24.
PMID: 19363600
Central circuits known to regulate food intake and energy expenditure also affect central cardiovascular regulation. For example, both the melanocortin and neuropeptide Y (NPY) peptide families, known to regulate food...